Mendus AB (publ)

Research Mendus AB (publ) (IMMU) on Bullrun: market cap SEK 355.82M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMMU
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 355.82M
• Financial periodFY2022
• RevenueSEK 3.38M
• Revenue growth10787.1%
• Net income-SEK 138.79M
• Free cash flow-SEK 121.43M

Valuation Snapshot

latest market cap is SEK 355.82M.

About Mendus AB (publ)

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2.

Frequently asked questions

What is Mendus AB (publ)'s market cap?

Mendus AB (publ)'s market capitalization is SEK 355.82M.

What does Mendus AB (publ) do?

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML);